Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Polymedco to Team up on North American Launch of Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Epigenomics said today it has reached a deal with Polymedco to jointly commercialize Epigenomics' Epi proColon colorectal cancer screen in North America.

The test is currently under review by the US Food and Drug Administration, and Germany-based Epigenomics has said that approval is anticipated later this year. Upon approval, Polymedco would deploy its dedicated colorectal cancer sales force, technical support staff, administration, logistics, and other support functions to launch and market the test, Epigenomics said.

Both firms will jointly work on marketing, launch, and development strategies, and collaborate on reimbursement efforts for Epi proColon. Epigenomics will continue to be responsible for manufacturing the test, and for supporting it "from the medical and regulatory point of view, including the activities necessary to achieve inclusion in major cancer screening guidelines" after FDA approval, it said.

As part of the deal, Epigenomics and Polymedco have agreed to a combined transfer price and to share profits, subject to minimum annual sales of test kits to Polymedco.

Based in Cortlandt Manor, NY, Polymedco is the largest provider of colorectal cancer screening tests in North America, according to Epigenomics, and has more than $50 million in annual sales of cancer diagnostic products. Its customer base includes more than 1,500 laboratories.

"Polymedco's commitment to the [colorectal cancer] screening space will accelerate our commercial rollout in North America and will mean a significant time and resource advantage for Epigenomics in the launch of Epi proColon," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.